303 related articles for article (PubMed ID: 20543579)
21. Epigenetic DNA hypermethylation: clinical applications in endometrial cancer (Review).
Muraki Y; Banno K; Yanokura M; Kobayashi Y; Kawaguchi M; Nomura H; Hirasawa A; Susumu N; Aoki D
Oncol Rep; 2009 Nov; 22(5):967-72. PubMed ID: 19787208
[TBL] [Abstract][Full Text] [Related]
22. Methylation analysis of tumor suppressor genes in endometroid carcinoma of endometrium using MS-MLPA.
Dvorakova E; Chmelarova M; Laco J; Palicka V; Spacek J
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2013 Dec; 157(4):298-303. PubMed ID: 23736679
[TBL] [Abstract][Full Text] [Related]
23. Hypermethylation of RAS effector related genes and DNA methyltransferase 1 expression in endometrial carcinogenesis.
Liao X; Siu MK; Chan KY; Wong ES; Ngan HY; Chan QK; Li AS; Khoo US; Cheung AN
Int J Cancer; 2008 Jul; 123(2):296-302. PubMed ID: 18404674
[TBL] [Abstract][Full Text] [Related]
24. Epigenetic fingerprint in endometrial carcinogenesis: the hypothesis of a uterine field cancerization.
Di Domenico M; Santoro A; Ricciardi C; Iaccarino M; Iaccarino S; Freda M; Feola A; Sanguedolce F; Losito S; Pasquali D; Di Spiezio Sardo A; Bifulco G; Nappi C; Bufo P; Guida M; De Rosa G; Abbruzzese A; Caraglia M; Pannone G
Cancer Biol Ther; 2011 Sep; 12(5):447-57. PubMed ID: 21709441
[TBL] [Abstract][Full Text] [Related]
25. APC, beta-catenin, and E-cadherin and the development of recurrent endometrial carcinoma.
Pijnenborg JM; Kisters N; van Engeland M; Dunselman GA; de Haan J; de Goeij AF; Groothuis PG
Int J Gynecol Cancer; 2004; 14(5):947-56. PubMed ID: 15361208
[TBL] [Abstract][Full Text] [Related]
26. DNA methylation as mechanism of apoptotic resistance development in endometrial cancer patients.
Fialkova V; Vidomanova E; Balharek T; Marcinek J; Kudela E; Hanysova S; Visnovsky J; Dobrota D; Hatok J
Gen Physiol Biophys; 2017 Dec; 36(5):521-529. PubMed ID: 29372685
[TBL] [Abstract][Full Text] [Related]
27. Gene Promoter Methylation in Endometrial Carcinogenesis.
Cornel KMC; Wouters K; Van de Vijver KK; van der Wurff AAM; van Engeland M; Kruitwagen RFPM; Pijnenborg JMA
Pathol Oncol Res; 2019 Apr; 25(2):659-667. PubMed ID: 30430425
[TBL] [Abstract][Full Text] [Related]
28. Promoter methylation and differential expression of pi-class glutathione S-transferase in endometrial carcinoma.
Chan QK; Khoo US; Chan KY; Ngan HY; Li SS; Chiu PM; Man LS; Ip PP; Xue WC; Cheung AN
J Mol Diagn; 2005 Feb; 7(1):8-16. PubMed ID: 15681469
[TBL] [Abstract][Full Text] [Related]
29. The high frequency of de novo promoter methylation in synchronous primary endometrial and ovarian carcinomas.
Furlan D; Carnevali I; Marcomini B; Cerutti R; Dainese E; Capella C; Riva C
Clin Cancer Res; 2006 Jun; 12(11 Pt 1):3329-36. PubMed ID: 16740754
[TBL] [Abstract][Full Text] [Related]
30. Comparison of DNA hypermethylation patterns in different types of uterine cancer: cervical squamous cell carcinoma, cervical adenocarcinoma and endometrial adenocarcinoma.
Kang S; Kim JW; Kang GH; Lee S; Park NH; Song YS; Park SY; Kang SB; Lee HP
Int J Cancer; 2006 May; 118(9):2168-71. PubMed ID: 16331610
[TBL] [Abstract][Full Text] [Related]
31. Current concepts in the pathology and epigenetics of endometrial carcinoma.
Arafa M; Somja J; Dehan P; Kridelka F; Goffin F; Boniver J; Delvenne P
Pathology; 2010 Dec; 42(7):613-7. PubMed ID: 21080868
[TBL] [Abstract][Full Text] [Related]
32. Importance of promoter methylation of GATA4 and TP53 genes in endometrioid carcinoma of endometrium.
Chmelarova M; Kos S; Dvorakova E; Spacek J; Laco J; Ruszova E; Hrochova K; Palicka V
Clin Chem Lab Med; 2014 Aug; 52(8):1229-34. PubMed ID: 24651021
[TBL] [Abstract][Full Text] [Related]
33. Genome-wide characterization of aberrant DNA methylation patterns and the potential clinical implications in patients with endometrial cancer.
Wang Y; Liu D; Jin X; Song H; Lou G
Pathol Res Pract; 2019 Jan; 215(1):137-143. PubMed ID: 30449607
[TBL] [Abstract][Full Text] [Related]
34. Not hMSH2 but hMLH1 is frequently silenced by hypermethylation in endometrial cancer but rarely silenced in pancreatic cancer with microsatellite instability.
Kondo E; Furukawa T; Yoshinaga K; Kijima H; Semba S; Yatsuoka T; Yokoyama T; Fukushige S; Horii A
Int J Oncol; 2000 Sep; 17(3):535-41. PubMed ID: 10938395
[TBL] [Abstract][Full Text] [Related]
35. High frequency of RASSF1A and RARb2 gene promoter methylation in morphologically normal endometrium adjacent to endometrioid adenocarcinoma.
Arafa M; Kridelka F; Mathias V; Vanbellinghen JF; Renard I; Foidart JM; Boniver J; Delvenne P
Histopathology; 2008 Nov; 53(5):525-32. PubMed ID: 18783461
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic mechanisms in endometrial cancer.
Stampoliou A; Arapantoni-Dadioti P; Pavlakis K
J BUON; 2016; 21(2):301-6. PubMed ID: 27273937
[TBL] [Abstract][Full Text] [Related]
37. Aberrant DNA hypermethylation of hMLH-1 and CDKN2A/p16 genes in benign, premalignant and malignant endometrial lesions.
Guida M; Sanguedolce F; Bufo P; Di Spiezio Sardo A; Bifulco G; Nappi C; Pannone G
Eur J Gynaecol Oncol; 2009; 30(3):267-70. PubMed ID: 19697618
[TBL] [Abstract][Full Text] [Related]
38. Hypermethylation in the p16 promoter region in the carcinogenesis of endometrial cancer in Japanese patients.
Yanokura M; Banno K; Susumu N; Kawaguchi M; Kuwabara Y; Tsukazaki K; Aoki D
Anticancer Res; 2006; 26(2A):851-6. PubMed ID: 16619479
[TBL] [Abstract][Full Text] [Related]
39. Status and significance of CpG island methylator phenotype in endometrial cancer.
Zhang QY; Yi DQ; Zhou L; Zhang DH; Zhou TM
Gynecol Obstet Invest; 2011; 72(3):183-91. PubMed ID: 21968189
[TBL] [Abstract][Full Text] [Related]
40. Epigenetic changes as prognostic predictors in endometrial carcinomas.
Farkas SA; Sorbe BG; Nilsson TK
Epigenetics; 2017 Jan; 12(1):19-26. PubMed ID: 27874289
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
